Search results
3 lis 2020 · The FDA’s Center for Drug Evaluation and Research has recommended withdrawing the approval of Makena for the prevention of recurrent preterm birth after a trial failed both to verify clinical...
25 mar 2022 · By Christina Jewett. March 25, 2022. By the time Brittany Bonds gave birth to her third son in the back of an ambulance 10 weeks before he was due, she no longer trusted the drug Makena. The drug...
8 mar 2023 · “ACOG is aware of the decision by the manufacturer of Makena to voluntarily withdraw the product—currently the only FDA-approved medication to help prevent recurrent spontaneous preterm birth—from the market in the coming months.
6 kwi 2023 · It means the medication, Makena, and its generics are no longer approved drug products and can no longer "lawfully be distributed in interstate commerce," according to an agency statement.
Hydroxyprogesterone caproate (Makena) is an injectable drug for the prevention of preterm birth, ie, birth prior to 37 weeks of gestation.
MAKENA® (hydroxyprogesterone caproate injection) October 17-19, 2022. Hearing with Respect to CDER’s Proposal to Withdraw Approval. Proposed Path Forward While Makena Remains on the Market....
17 lut 2022 · The drug Makena doesn't reduce the risk of preterm birth, a study found, and the FDA recommended it be taken off the market. Its maker has refused.
